{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05251727",
            "orgStudyIdInfo": {
                "id": "ART-123.PN101"
            },
            "organization": {
                "fullName": "Veloxis Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients",
            "officialTitle": "Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "assess-safety-and-tolerability-of-art-folfox-bevacizumab-in-metastatic-colorectal-cancer-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-07",
            "studyFirstSubmitQcDate": "2022-02-11",
            "studyFirstPostDateStruct": {
                "date": "2022-02-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-31",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Veloxis Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab",
            "detailedDescription": "To compare the safety and tolerability of ART-123 to placebo in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab"
        },
        "conditionsModule": {
            "conditions": [
                "Chemotherapy-induced Peripheral Neuropathy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Lowest Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)",
                    "interventionNames": [
                        "Drug: thrombomodulin alfa"
                    ]
                },
                {
                    "label": "Low Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)\"",
                    "interventionNames": [
                        "Drug: thrombomodulin alfa"
                    ]
                },
                {
                    "label": "Medium Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)\"",
                    "interventionNames": [
                        "Drug: thrombomodulin alfa"
                    ]
                },
                {
                    "label": "High Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)\"",
                    "interventionNames": [
                        "Drug: thrombomodulin alfa"
                    ]
                },
                {
                    "label": "Highest Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Lyophilized ART-123 reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)\"",
                    "interventionNames": [
                        "Drug: thrombomodulin alfa"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Lyophilized placebo reconstituted with sterile water for injection and administered by intravenous infusion over approximately 30 minutes prior to chemotherapy on Day 1 of cycle (for up to 3 cycles including bevacizumab)\"",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "thrombomodulin alfa",
                    "description": "Weight based dose of reconstituted treatment",
                    "armGroupLabels": [
                        "High Dose",
                        "Highest Dose",
                        "Low Dose",
                        "Lowest Dose",
                        "Medium Dose"
                    ],
                    "otherNames": [
                        "ART-123"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Weight based dose of reconstituted treatment",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number and Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)",
                    "description": "Number and percentage of participants experiencing one or more adverse events which occurred or worsened in severity after the start of the first dose of investigational medicinal product (IMP)",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) through End of Treatment (EOT) visit; planned for 6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Serious TEAEs",
                    "description": "Number and percentage of participants experiencing one or more serious adverse events which occurred or worsened in severity after the start of the first dose of IMP",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) through EOT visit; planned for 6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with TEAEs Leading to Death",
                    "description": "Number and percentage of participants with TEAEs that resulted in death",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) through EOT visit; planned for 6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with TEAEs Leading to IMP Discontinuation",
                    "description": "Number and percentage of participants with TEAEs that lead to discontinuation of IMP",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) through planned third IMP dose; planned for 4 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Bleeding Events",
                    "description": "Number and percentage of participants experiencing bleeding events",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) through EOT visit; planned for 6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Serious Bleeding Events",
                    "description": "Number and percentage of participants with bleeding events that represent serious adverse events",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) through EOT visit; planned for 6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Dose Limiting Toxicity (DLT)",
                    "description": "Number and percentage of participants experiencing DLT",
                    "timeFrame": "From start of first IMP dose (Cycle 1, Day 1) until the start of the third IMP dose; planned for 4 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Abnormal Complete Blood Count (CBC) Results",
                    "description": "Descriptive statistics will summarize the following by cohort: red blood cell count, hemoglobin, hematocrit, white blood cell count, white blood cell differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), and platelet count",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Abnormal Serum Chemistry Results",
                    "description": "Descriptive statistics will summarize the following by cohort: aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, lactate dehydrogenase, total bilirubin, total protein, albumin, blood urea nitrogen, creatinine, glucose, and electrolytes (sodium, potassium, chloride)",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Abnormal Coagulation Panel Results",
                    "description": "Descriptive statistics will summarize the following by cohort: international normalized ratio (INR), activated partial thromboplastin time (APTT)",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Abnormal Qualitative Urinalysis Results",
                    "description": "Qualitative summary of the following by cohort: protein, glucose, and occult blood",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Abnormal Vital Signs",
                    "description": "Descriptive statistics will summarize the following by cohort: body temperature, pulse, and blood pressure",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Number and Percentage of Participants with Anti-ART-123 Antibodies",
                    "description": "Number and Percentage of Participants with detectable anti-ART-123 antibodies; samples testing positive for anti-ART-123 antibodies will be tested for the presence of neutralizing antibodies",
                    "timeFrame": "6 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Plasma Concentrations of Thrombomodulin",
                    "description": "Plasma concentrations of thrombomodulin associated with Cycle 1 dosing (each cycle is 14 days)",
                    "timeFrame": "Cycle 1, Day 1 (each cycle is 14 days)"
                },
                {
                    "measure": "Plasma Concentrations of 5-fluorouracil (5-FU)",
                    "description": "Plasma concentrations of 5-FU associated with Cycle 1 dosing (each cycle is 14 days)",
                    "timeFrame": "Cycle 1, Day 1 (each cycle is 14 days)"
                },
                {
                    "measure": "Plasma Concentrations of Oxaliplatin",
                    "description": "Plasma concentrations of oxaliplatin associated with Cycle 1 and Cycle 3 dosing (each cycle is 14 days)",
                    "timeFrame": "Cycle 1, Day 1 and Cycle 3, Day 1 (each cycle is 14 days)"
                },
                {
                    "measure": "Serum Concentrations of Bevacizumab",
                    "description": "Serum concentrations of bevacizumab associated with Cycle 1 and Cycle 3 dosing (each cycle is 14 days)",
                    "timeFrame": "Cycle 1, Day 1 and Cycle 3, Day 1 (each cycle is 14 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years of age or older\n* Metastatic colorectal cancer; pathologically confirmed adenocarcinoma of the colon or rectum\n* ECOG performance status of 0 or 1\n* The most recent laboratory findings (including for liver and kidney) within 14 days prior to randomization remain within acceptable ranges Willingness of the patient and the sexual partner to use a highly effective contraceptive method during the course of the study\n* Able to sufficiently understand the clinical study and give written informed consent\n\nExclusion Criteria:\n\n* History of major hemorrhage\n* High risk of hemorrhage\n* History of other malignancies\n* Active ulcer\n* Patients using anti-coagulants and fibrinolytic drugs\n* Active Hepatitis B, or known HBs antigen positive\n* Prior treatment history with thrombomodulin alfa\n* Administration of another investigational medicinal product within 30 days prior to randomization\n* Patient is pregnant (positive urine human chorionic gonadotropin) or breastfeeding or intends to get pregnant during the Treatment period\n* Patients otherwise deemed as inappropriate to participate in the study by the Investigator",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pamela Allton",
                    "role": "CONTACT",
                    "phone": "984-301-2320",
                    "email": "pal@veloxis.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Libbie McKenzie, MD FASN",
                    "affiliation": "Veloxis Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Beverly Hills Cancer Center",
                    "status": "RECRUITING",
                    "city": "Beverly Hills",
                    "state": "California",
                    "zip": "90210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.07362,
                        "lon": -118.40036
                    }
                },
                {
                    "facility": "UCLA Dept. of Medicine - Hematology/Oncology",
                    "status": "WITHDRAWN",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Eastern Connecticut Hematology & Oncology Associates",
                    "status": "WITHDRAWN",
                    "city": "Norwich",
                    "state": "Connecticut",
                    "zip": "06360",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.52426,
                        "lon": -72.07591
                    }
                },
                {
                    "facility": "Mid-Florida Hematology & Oncology Centers",
                    "status": "TERMINATED",
                    "city": "Orange City",
                    "state": "Florida",
                    "zip": "32763",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.94888,
                        "lon": -81.29867
                    }
                },
                {
                    "facility": "Horizon Oncology Research, Inc.",
                    "status": "RECRUITING",
                    "city": "Lafayette",
                    "state": "Indiana",
                    "zip": "47905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4167,
                        "lon": -86.87529
                    }
                },
                {
                    "facility": "American Oncology Partners, P.A.",
                    "status": "RECRUITING",
                    "city": "Bethesda",
                    "state": "Maryland",
                    "zip": "20817",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pam Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.98067,
                        "lon": -77.10026
                    }
                },
                {
                    "facility": "Tufts Medical Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Henry Ford Health System",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "St. Vincent Frontier Cancer Center",
                    "status": "RECRUITING",
                    "city": "Billings",
                    "state": "Montana",
                    "zip": "59101",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.78329,
                        "lon": -108.50069
                    }
                },
                {
                    "facility": "Englewood Hospital and Medical Center",
                    "status": "RECRUITING",
                    "city": "Englewood",
                    "state": "New Jersey",
                    "zip": "07631",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.89288,
                        "lon": -73.97264
                    }
                },
                {
                    "facility": "Site #115",
                    "status": "WITHDRAWN",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "TERMINATED",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Prisma Health Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29605",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "Nashville Oncology Associates, PC",
                    "status": "TERMINATED",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Site #120",
                    "status": "WITHDRAWN",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Site #114",
                    "status": "WITHDRAWN",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77024",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "MultiCare Regional Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tacoma",
                    "state": "Washington",
                    "zip": "98405",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.25288,
                        "lon": -122.44429
                    }
                },
                {
                    "facility": "Yokohama City University Medical Center",
                    "status": "RECRUITING",
                    "city": "Yokohama-shi",
                    "state": "Kanagawa-ken",
                    "zip": "232-0024",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                },
                {
                    "facility": "Kurashiki Central Hospital",
                    "status": "RECRUITING",
                    "city": "Kurashiki-shi",
                    "state": "Okyama",
                    "zip": "710-8602",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.58333,
                        "lon": 133.76667
                    }
                },
                {
                    "facility": "NHO Kyushu Cancer Center",
                    "status": "RECRUITING",
                    "city": "Fukuoka-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.6,
                        "lon": 130.41667
                    }
                },
                {
                    "facility": "Gifu University Hospital",
                    "status": "RECRUITING",
                    "city": "Gifu-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.42291,
                        "lon": 136.76039
                    }
                },
                {
                    "facility": "Kagawa University Hospital",
                    "status": "RECRUITING",
                    "city": "Kita-gun",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ]
                },
                {
                    "facility": "Kitakyushubyoin Kitakyusyu General Hospital",
                    "status": "RECRUITING",
                    "city": "Kitakyushu-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.85181,
                        "lon": 130.85034
                    }
                },
                {
                    "facility": "Kumpukai Sano Hospital",
                    "status": "RECRUITING",
                    "city": "Kobe-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.6913,
                        "lon": 135.183
                    }
                },
                {
                    "facility": "NHO Shikoku Cancer Center",
                    "status": "RECRUITING",
                    "city": "Matsuyama-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.83916,
                        "lon": 132.76574
                    }
                },
                {
                    "facility": "Kochi Medical School Hospital",
                    "status": "RECRUITING",
                    "city": "Nankoku-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.56943,
                        "lon": 133.64937
                    }
                },
                {
                    "facility": "NHO Osaka National Hospital",
                    "status": "RECRUITING",
                    "city": "Osaka-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.69374,
                        "lon": 135.50218
                    }
                },
                {
                    "facility": "Osaka General Medical Center",
                    "status": "RECRUITING",
                    "city": "Osaka-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.69374,
                        "lon": 135.50218
                    }
                },
                {
                    "facility": "Tonan Hospital",
                    "status": "RECRUITING",
                    "city": "Sapporo-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.06667,
                        "lon": 141.35
                    }
                },
                {
                    "facility": "Shizuoka Cancer Center",
                    "status": "RECRUITING",
                    "city": "Sunto-gun",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ]
                },
                {
                    "facility": "University of Tsukuba Hospital",
                    "status": "RECRUITING",
                    "city": "Tsukuba-shi",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Pamela Allton",
                            "role": "CONTACT",
                            "phone": "010-1-984-301-2320",
                            "email": "pal@veloxis.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.2,
                        "lon": 140.1
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010523",
                    "term": "Peripheral Nervous System Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13432",
                    "name": "Peripheral Nervous System Diseases",
                    "asFound": "Peripheral Neuropathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "relevance": "LOW"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                }
            ]
        }
    },
    "hasResults": false
}